|Articles|May 11, 2022
- Pharmaceutical Executive-05-01-2022
- Volume 42
- Issue 5
Pharmaceutical Executive, May 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
Restoring Hope in Mental Illness Is a Collective Missionover 3 years ago
Upward Mobility: Optimizing Your Pharma T-Profileover 3 years ago
Breadth, Depth, and Enterpriseover 3 years ago
Rising to the Taskover 3 years ago
Lessons Learnedover 3 years ago
Persistence Pays Offover 3 years ago
Authenticity in Actionover 3 years ago
Challenging Assumptionsover 3 years ago
Steady at the ControlsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
